Orphazyme's fate as a biotech company may be at stake when the US Food and Drug Administration (FDA) decides whether arimoclomol can be approved as a treatment for the rare metabolic disorder Niemann-Pick type C (NPC), says Danske Market's Senior Analyst Thomas Bowers.
"Clearly, its existence will be threatened if it gets a clear no and arimoclomol never gets to be an NPC product in the US," the analyst tells MedWatch.
Get full access for you and your coworkers.
Start a free company trial todayAlready a member? Log in.
More from MedWatch
GN Hearing top exec stops after 17 years – replacement found within own ranks
The CEO of hearing company GN Hearing's US subsidiary Audigy is now retiring after 17 years in the hot seat. The company, which was acquired by GN Hearing in 2016, has found his replacement within own ranks.
Pharma industry is discretely working against a global tax agreement
The pharmaceutical industry is fighting against a threat to companies' bottom lines: a global agreement which will harmonize corporation tax.
Pfizer upgrades guidance for sales of covid-19 vaccine
The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
Astrazeneca shot shows no increased clot risk after two doses
Blot clots are not more likely after second Astrazeneca jab, data published in The Lancet suggests.
Boston Scientific reports significant growth in endoscopy business – grows 54 percent
In Q2, medtech firm Boston Scientific sold significantly more endoscopy products, which is the core business area of Danish company Ambu. The US giant is upgrading its guidance for the whole year.
(Senior) Regulatory Science Specialist - IWA Consulting 
Medical Writer - Vaccibody 
Business developer within Medical Diagnostics 
Sponsor Oversight Lead - Genmab 
Regulatory Affairs Professional, CMC - ALK 
Employee for regulatory department 
Principal Scientist, Protein Drug Discovery & Development - Y-mAbs Therapeutics A/S 
Principal Scientist, In Vivo Pharmacology 
Market Director, Alfanordic 
KLIFO is looking for a Senior CMC Expert/Senior CMC Project Manager for our Copenhagen office 
Manager/Associate Director Regulatory Affairs - Ascendis Pharma 
Senior Clinical Supply Manager - Lundbeck